

isothermic incubation at 65°C for 15 minutes, followed by an ethanol precipitation step. Alternatively, a single-cycle thermal cycler procedure is included for primers whose TM values or structures are not suitable for reactions at 65°C.

On the average, the Ladderman Dideoxy Sequencing Core Kit produces 940 bases of data when used with LI-COR instrumentation. The kit consists of enough materials for 100 four-lane reactions, although the fluorescent primers are not included.

Visible Genetics, Inc.

HLA Class I-A, B, & C Kits

HLA Class II-DRB1 Kit

TruGeneTM HIV Genotyping GeneKitTM

Core Sequencing Kit

Visible Genetics, Inc. (VGI) develops, manufactures, and markets automated DNA sequencing systems designed to analyze genes linked to disease. The company offers fully integrated sequencing kits based on PCR and optimized for clinical DNA sequencing and analysis using its OpenGeneTM automated sequencing system.

Recently, VGI announced the availability of four new DNA GeneKits designed for sequenced-based research of the A, B, and C loci of the Class I, and the DRB1 locus of the Class II, HLA genes. These genes are important genetic markers used for matching bone marrow transplant donors and recipients. These kits represent an important advance in ensuring proper matches.

VGI's TruGene HIV Genotyping GeneKit is a fluorescent primer- based kit currently being tested. This kit is designed to sequence the Protease and RT regions of the HIV genome using CLIPTM, a DNA sequencing technique designed to directly sequence small amounts of amplified templates. The highly variable RT and Protease regions are important to the virus's ability to develop drug resistance. Other kits in development include tests for RB1, a gene associated with eye cancers in children; p53, a gene found in solid tumors in many cancers; and the human papilloma virus, which is believed to be responsible for cervical cancer.

Pushed onward by the continuing demands for faster and longer sequence reads, sequencing kit and instrumentation manufacturers constantly upgrade their products. Indeed, several of the marketing and product managers interviewed during the preparation of this profile mentioned that their companies are working hard at developing new polymerases and other ideas to improve automated DNA sequencing. Particularly noteworthy is the introduction of sequencing kits with specific clinical and other applications. So be on the lookout for new products as fluorescent automated DNA sequencing technology continues to improve and expand into new territories.

Michael Brush is an Associate Scientist and Radiation Safety Officer at Hitachi Chemical Company in Irvine, Calif. He can be reached online at MDBrush@compuserve.com.



Chart 1

The Scientist 11[22]:18, Nov. 10, 1997

[Previous](#) [Issue Content](#) [Next](#)

© Copyright 1997, The Scientist, Inc. All rights reserved.

We welcome your opinion. If you would like to comment on this article, please write us at editorial@the-scientist.com

[News](#) | [Opinions & Letters](#) | [Research](#) | [Hot Papers](#) | [LabConsumer](#) | [Profession](#)
[About The Scientist](#) | [Jobs](#) | [Classified](#) | [Web Registration](#) | [Print Subscriptions](#) | [Advertiser Information](#)